The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets.
Experiments in MPTP-treated non-human primates testing potential antiparkinsonian action have shown both, beneficial and adverse effects of gutamate receptor antagonists. To investigate this matter further, the novel competitive NMDA antagonist CGP40.116 was administered systemically to three adult MPTP-treated marmosets. When coadministered subcutaneously with a subthreshold dose of L-DOPA, 2 mg/kg, CGP40.116 25-250 micrograms/kg, increased locomotor activity. However, when administered alone, CGP40.116 had no effect on locomotor activity.
Wüllner
U
U
Eberhard-Karls University, Dept. of Neurology, Tübingen, F.R.G.
Kupsch
A
A
Arnold
G
G
Renner
P
P
Scheid
C
C
Scheid
R
R
Oertel
W
W
Klockgether
T
T
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002144:Callithrix; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D007980:Levodopa / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects*; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors*
C064539:2-amino-4-methyl-5-phosphono-3-pentenoic acid; D007980:Levodopa; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine